![]() | ![]() |
Formats:
|
||||||||||||||
Copyright © 2007 Szebenyi et al; licensee BioMed Central Ltd. Hook2 contributes to aggresome formation 1Center for Basic Neuroscience, University of Texas, Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, Texas 75390-9111, USA 2Department of Physiology, University of Texas, Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, Texas 75390-9040, USA 3Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Irving TX 75063-2648, USA Corresponding author.Györgyi Szebenyi: gspb/at/prodigy.net; W Christian Wigley: chris.wigley/at/reatapharma.com; Branden Hall: branden.hall/at/gmail.com; Aaron Didier: Aaron.Didier/at/Vanderbilt.Edu; Michelle Yu: rosayu99/at/yahoo.com; Philip Thomas: philip.thomas/at/utsouthwestern.edu; Helmut Krämer: hkrame/at/mednet.swmed.edu Received January 3, 2007; Accepted May 31, 2007. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article has been cited by other articles in PMC.Abstract Background Aggresomes are pericentrosomal accumulations of misfolded proteins, chaperones and proteasomes. Their positioning near the centrosome, like that of other organelles, requires active, microtubule-dependent transport. Linker proteins that can associate with the motor protein dynein, organelles, and microtubules are thought to contribute to the active maintenance of the juxtanuclear localization of many membrane bound organelles and aggresomes. Hook proteins have been proposed to serve as adaptors for the association of cargos with dynein for transport on microtubules. Hook2 was shown to localize to the centrosome, bind centriolin, and contribute to centrosomal function. Results Here we show that overexpression of hook2 promotes the accumulation of the cystic fibrosis transmembrane regulator in aggresomes without altering its biochemical properties or its steady state level. A dominant negatively acting form of hook2 that lacks the centriolin binding C-terminal inhibits aggresome formation. Conclusion We propose that hook2 contributes to the establishment and maintenance of the pericentrosomal localization of aggresomes by promoting the microtubule-based delivery of protein aggregates to pericentriolar aggresomes. Background Intracellular protein aggregates form when misfolded proteins accumulate in cells because of malfunctioning or overloading of either the quality control pathways that recognize and route defective proteins for degradation or the elements of the actual degradative pathway [1]. Aggregates distribute randomly throughout the cell and can be associated with pathogenic changes; for example, they may block microtubule-based transport [2] or sequester components of the ubiquitin-proteasome system [3]. One of the cellular responses to potentially pathogenic aggregates of misfolded proteins is their dynein-mediated retrograde transport along microtubules to the centrosome [4,10] where they are enriched together with elements of the protein-folding and degradation machinery in pericentriolar structures, called aggresomes [4-9]. Aggresomes may protect cells by sequestering harmful protein aggregates and enhancing their degradation either by concentrating them together with proteasome subunits or by triggering their uptake into autophagosomes and delivery to lysosomes [10]. Experimentally induced aggresomes stirred general interest, because they are similar in composition and morphology to inclusion bodies found in brains of patients who died of neurodegenerative diseases [6,7,9,11]. The most studied protein that accumulates in aggresomes is the cystic fibrosis transmembrane regulator (CFTR). Similar to some other integral membrane proteins that have large hydrophobic regions [12], over-expressed CFTR is inefficiently processed [13]. This is even more pronounced for a prevalent mutation in cystic fibrosis patients, the ΔF508-CFTR deletion mutant, which is degraded by the proteasome [14,15]. When the degradation of CFTR is inhibited, CFTR accumulates in pericentrosomal aggresomes [7,9]. The retrograde transport of CFTR and other misfolded proteins depends on the integrity of the microtubule cytoskeleton and the association of dynein with the cargo-binding dynactin complex [4,16,17]. Linker proteins that associate with dynein, organelles, and microtubules facilitate the loading of cargos for retrograde transport and contribute to the establishment and active maintenance of the juxtanuclear localization of organelles [18], and thus they may play a role in the formation of aggresomes. Hook-related proteins were proposed to function as linker proteins [19]. Hook proteins are composed of a conserved N-terminal domain, a central coiled-coil, and a more divergent C-terminal domain that has been implicated in the binding of each of the hook proteins to a different class of organelles [20,21]. Data from several studies suggested that hook proteins may modulate microtubule based transport. The first identified member of the hook family, Drosophila hook, was originally discovered based on a defect in endocytic trafficking [22,23]. The characterization of a C. elegans homolog, zyg-2, revealed a function in binding and linking centrosomes to nuclei through the microtubule cytoskeleton [24]. We recently found that mammalian hook2 also localizes to centrosomes, in this case through a direct interaction with centriolin [21]. In addition, altering hook2 levels or function led to the accumulation of both endogenous and overexpressed proteins at the centrosome, raising the possibility that hook2 may influence aggresome formation. Here, we are using mutant CFTR, which is well-known to accumulate in aggresomes [7,9], to examine whether hook2 contributed to the accumulation of misfolded proteins around the centrosome. We found that altering hook2 activity by overexpressing hook2 or using dominant-negative hook2 proteins changed the distribution of aggresome constituents. We have considered the possibility that hook2 induced changes in the activities of the protein degradation pathway, such as ubiquitination, however we found no evidence for hook2-induced biochemical changes in CFTR. Therefore, we propose a model wherein hook2 influences aggresome formation by interfering with the functioning of the centrosome in the coordination of vectorial intracellular transport. Results Hook2 co-localizes with aggresomes at the centrosome Endogenous and overexpressed hook2 localizes to the centrosome, as we previously showed by colocalization with the centrosomal markers ninein and gamma-tubulin, at the center of the radial microtubule array [21]. The juxtanuclear localization of over-expressed hook2-constructs resembled the centrosomal distribution of endogenous hook2 in an accentuated form [Fig. [Fig.1A1A
Because overexpressed hook2 accumulated around the centrosome, we wondered whether hook2 and components of aggresomes co-localized. To induce aggresomes experimentally, the proteasome inhibitor lactacystin [26] was applied to cells that co-expressed ΔF508-CFTR and hook2. After 12 h of lactacystin treatment, aggregates of CFTR co-localized with hook2 in juxtanuclear aggresomes (Fig. 1C–E Over-expressed hook2 promotes the juxtanuclear accumulation of aggresome components Hook2 not only co-localized with lactacystin-induced and CFTR-containing aggresomes, but also induced aggresome formation in the absence of proteasome inhibitors and CFTR, as indicated by the juxtanuclear accumulation of endogenous hsc70, ubiquitin, and the 20S component of the proteasome in hook2 transfected cells (Fig. 1F–H Dynein-mediated transport of cargo to aggresomes is necessary for their formation, but in this process the dynein motor also becomes concentrated within aggresomes [4,16]. Consistent with these results, we observed that aggresomes induced by hook2 were enriched in dynein, even in the absence of lactacystin. This accumulation was visible already at the earliest stages in hook2-induced aggresome formation when little hook2 had accumulated (Fig (Fig1I)1I Moderately overexpressed CFTR is found throughout the secretory system including the ER and on the plasma membrane (Fig. (Fig.2A2A
Co-expression with hook2 caused a dramatic increase in the frequency of ΔF508-CFTR aggresomes at each time point. The hook2-induced increase of CFTR in aggresomes was most obvious without treatment with lactacystin (from 2% to 22%, n > 1000; Fig. Fig.2B,2B The effect of hook2 on the induction of aggresomes without lactacystin treatment was even more pronounced when the distribution of ΔF508-CFTR was considered separately in cells with hook2 accumulation at the centrosome and in cells with diffuse hook2: 54% of cells with centrosomal hook2 had ΔF508-CFTR-positive aggresomes compared to only 3% of cells with a diffuse hook2 distribution (Fig. (Fig.2C).2C We also examined the effect of CFTR co-expression on the distribution of hook2. If the effect of hook2 on CFTR accumulation in aggresomes is only due to an unspecific increase in the level of misfolded proteins, then misfolded CFTR should have a reciprocal effect on hook2. However, in contrast to the dramatic effect of hook2 on ΔF508-CFTR localization, ΔF508-CFTR had no effect on hook2 localization. Hook2 juxtanuclear aggregates were seen in the same percentage of cells with and without ΔF508-CFTR (Fig. (Fig.2D).2D Interference with hook2 function alters CFTR aggresome formation To further test a possible role for hook2 in aggresome formation, we attempted different approaches to interfere with hook2 function. Because so far we have not been successful in significantly knocking down hook2 levels by RNAi, we expressed hook2 truncations that are predicted to act as dominant negatives. This approach has previously been successful in Drosophila where phenotypes very similar to those of the hook11 null allele resulted from the expression of dHook proteins that were truncated at their N- or C-termini but retained the coiled-coil dimerization domain [22]. Thus, we tested whether corresponding hook2 truncation mutants altered aggresome formation. We counted the number of cells with distinct CFTR distributions in Vero cells (Figure (Figure3A)3A
In the absence of lactacystin, CFTR distribution was mildly altered by co-expression of ΔC-hook2: it reduced the fraction of cells with CFTR aggresomes to 1% from 3% observed with CFTR alone, and increased the fraction of cells with aggregated CFTR from 5% to 9%. By contrast, under these conditions co-expression of full-length hook2 increased the fraction of cells with CFTR in aggresomes from 3% to 24%. This effect is specific, as co-expression of hook3 or the hook chimeras 332 and 233, which contain mostly hook3 sequences, did not increase CFTR aggregation. The presence of lactacystin (Figure (Figure3B)3B N-terminally truncated hook2 had an effect similar to that of ΔC-hook2. In the presence of lactacystin, co-expression of ΔN-hook2 reduced by ~50% the percentage of cells with ΔF508-CFTR in aggresomes compared to CFTR-only transfected cells. Similar results were obtained in five separate experiments in VERO cells (Figure (Figure3B)3B In an attempt to pinpoint a specific domain in hook2 responsible for its effect on aggresome formation, we tested several chimeras between hook2 and hook3. We found that chimeras of hook2 and the C- or the N-terminus of hook3 enhanced aggresome formation in the absence of lactacystin (Fig. (Fig.3A).3A Hook2 changes CFTR distribution without an obvious biochemical change Expression of hook2 could affect aggresome formation by altering biochemical properties of CFTR that cause it to aggregate or by changing the degree to which aggregated CFTR is transported to aggresomes. To distinguish between these possibilities, first we investigated whether hook2 coexpression changed the biochemical properties of CFTR. Lactacystin induced a shift to an insoluble high-molecular weight ubiquitinated form of ΔF508-CFTR [Figure 4A–B
In addition, we also explored whether co-expression of hook2 truncations modified CFTR. Immunoblots of Triton X-100 extracts from cells co-expressing ΔF508-CFTR and either ΔN-hook2 or ΔC-hook2 showed that these dominant-negative constructs did not alter the electrophoretic mobility pattern of ΔF508-CFTR or its solubility, whether lactacystin was present or not (Fig. (Fig.5A).5A
Discussion Hook proteins constitute a family of coiled-coil proteins that have been implicated in the positioning of a variety of organelles [27]. In this study we present experiments suggesting that hook2 may function in the positioning or formation of aggresomes, pericentriolar accumulations of misfolded proteins, proteasomes and chaperones. Hook2 expression enhanced the recruitment of aggresome components to the centrosome, in addition to the molecular motor dynein which previously had been shown to accumulate in aggresomes and is necessary for their formation [4,16]. Furthermore, the accumulation of CFTR into aggresomes was inhibited by a hook2 C-terminal truncation that is modelled after a dominant-negative form of the Drosophila hook protein [23] and lacks the centriolin binding region of hook2 [21]. Expression of truncation mutants or full-length hook2 also altered the distribution of the centrosomal proteins PCM-1 and ninein [21], indicating that the effect of hook2 on aggresome formation may result from its primary role in regulating the activities of the centrosome. A first clue to a possible function of hook2 in aggresome formation comes from its subcellular localization at the centrosome. Pericentrosomal accumulation in aggresomes has been observed for many overexpressed proteins [10], but several of our findings argue for hook2 playing a more active role than just being a misfolded substrate for aggresome formation. Importantly, centrosomal localization did not depend on overexpression-induced misfolding, but was also observed for endogenous hook2 [21]. In addition, dominant-negative hook2 proteins reduced the accumulation of co-expressed ΔF508-CFTR in aggresomes whereas wild-type hook2 enhanced it. This is unlikely to be due to the co-aggregation of misfolded hook2 and CFTR proteins, because aggregation is a specific process; even if two misfolded proteins are co-expressed they accumulate in separate aggregates [8]. A mechanism by which hook2 might enhance the formation of CFTR containing aggresomes is through the inhibition of proteasome activity by overexpressed hook2, as had been observed for some misfolded proteins [3,28]. However, for hook2, we do not consider this as a likely explanation for the following reasons: First, even when proteasome activity was inhibited by lactacystin, hook2 further enhanced aggresome formation compared to lactacystin on its own (Fig. (Fig.2),2 Instead, hook2 may act on the dynein-mediated retrograde transport of aggresome components. Aggresome formation depends on retrograde transport of misfolded protein aggregates and other aggresome components by cytoplasmic dynein, since nocadozole-induced depolymerization and dynamitin expression interfere with aggresome formation [4,16]. As a consequence of changes in microtubule dependent transport, dynein itself can accumulate in aggresomes [Fig. 1I, J Support for a model in which hook2 participates in the dynein-mediated retrograde transport of aggresome components comes from observations of its distant C. elegans homolog zyg-12. In early C. elegans embryos, zyg-12 is necessary for the positioning of centrosomes close to nuclei [24], a process that requires the recruitment of dynein and the dynein-associated proteins lis-1 and arp-1 to the nuclear membrane [24]. Two-hybrid analysis has suggested a direct interaction between zyg-12 and the dynein light intermediate subunit [24]. However, our attempts to demonstrate a direct interaction between hook2 and cytoplasmic dynein have not been successful and we did not notice significant co-localization of hook2 with peripheral CFTR aggregates. Alternatively, hook proteins may indirectly participate in retrograde transport by functioning as transient linker proteins or attachment factors during the loading of cargo onto the dynein/dynactin complex [18,27,29]. Such linker proteins may also contribute to the anchoring and stabilization of microtubules [29], functions traditionally attributed to centrosomes. Consistent with such a role of centrosomal hook2, dominant-negative hook2 constructs interfered with the regrowth of microtubules after their nocodazole-induced depolymerization [21]. In this context, it is also interesting to notice that the two hook2/3 chimeras that promoted aggresome formation in the absence of lactacystin (Fig. (Fig.3A)3A A possible function of hook2 in modulating the retrograde transport of non-membranous protein particles is in line with observations that implicated other members of the hook family in modulating the movement and anchoring of organelles. Interference with hook3 function causes the dispersal of the Golgi complex [20], similar to the effect of overexpression of the dynamitin subunit of the dynein/dynactin complex [30,31]. Furthermore, hook1 is abundant in differentiating murine spermatids where it localizes to the ends of the microtubule manchette at the time of flagellar development. A deletion in the hook1 gene underlies the mouse mutation abnormal spermatozoon head shape (azh). Azh males have reduced fertility, a phenotype that correlates with malpositioning of the manchette, abnormal shaping of the spermatid nucleus, and fragile sperm tails [32]. The displacement of the manchette, a spermatid-specific microtubule array in azh mice [32] is consistent with an involvement of hook1 in the anchoring of microtubules. These observations in azh mutant mice lacking hook1 and our finding that hook2 localizes to centrosomes, at least in part through a direct interaction with centriolin [21], suggest an alternative model in which the effects of hook proteins on transport are mediated through directly altering the functioning of the centrosome. One major role of centrosomes is to support the nucleation and organization of microtubules [33,34] and thus ultimately to control vectorial protein transport. In a previous study, we could not detect an effect of hook2 on microtubule nucleation but our data revealed a contribution of hook2 to the maintenance of the radial arrangement of microtubules [21]. However, since cytoplasmic dynein also transports centrosomal proteins and microtubules [35-37], it is not straightforward to distinguish direct effects on centrosomes from the indirect consequences of abnormal retrograde transport. Future studies to unravel the molecular mechanisms by which hook2 contributes to the formation of aggresomes should take into consideration that hook2 may modulate microtubule-dependent retrograde transport. Conclusion Taken together with previous findings that hook2 localizes to centrosomes, binds directly to centriolin and that interference with hook2 function disturbs the radial organization of microtubules, our results indicate that centrosomally localized hook2 promotes the generation or maintenance of aggresomes when misfolded proteins accumulate in cells. Based on the functions observed for other hook homologs [20,24,32] and the defects in the radial organization of microtubules upon interference with hook2 function [21], we propose that hook2 function is required for the microtubule-based delivery of protein aggregates to pericentriolar aggresomes. Methods Cell lines The following cell lines were used in this study, with tissue and species source for each line in parenthesis: HEK 293 (human embryonic kidney), VERO (adult African green monkey kidney); these cell lines were obtained from ATCC (American Type Culture Collection; Manassas, VA) and maintained as recommended by ATCC. Sources of Antibodies Polyclonal antibodies against hook2 (aa 427–719) and hook3 (423–630) have been described [20]; these were diluted 1:200–1:400 to detect endogenous hooks and 1:400–1:600 to detect overexpressed hooks by immunohistochemistry and 1:2,000–1:10,000 for immunoblotting. Anti-tubulin, dynein 74.1, anti-heat shock protein 70 and rabbit ubiquitin antibodies were from Sigma (Saint Louis, MO; sigma-aldrich.com); GM130 from BD Transduction Labs (bdbiosciences.com); FK1, anti-ubiquitin, and anti-20S proteasome antibodies from Biomol International (biomol.com); mouse anti-CFTR (mAb3A7) or mouse anti-human CFTR (C-24-1) at 1:150 for immunostaining and immunoprecipitation, 1:1000 for immunoblotting (Research Diagnostics, Inc.; Flers, NJ). Secondary antibodies for immunoblots were horseradish peroxidase labeled goat anti-mouse and anti-rabbit from Bio-Rad, each used at a dilution of 1:10,000. Secondary antibodies for immunofluorescence were Alexa-488, -564, or -594 conjugated goat anti-mouse or goat anti-rabbit antibodies from Molecular Probes (Eugene, OR), each used at a dilution of 1:400. Immunoblotting and immunoprecipitation Equal amounts of cell extracts, or cell homogenates were separated by SDS-PAGE gels (Criterion Precast Gels; Bio-Rad; Hercules, CA) and transferred to nitrocellulose (Schleicher and Schuell; Keene, NH). Prior to the application of antibodies, membranes were blocked in 3% non-fat dry milk in wash buffer (20 mM Tris-HCl pH 7.5; 150 mM NaCl; 1% Tween-20) for 1 h at RT or over-night at 4°C. Primary antibodies were applied in block for 1–2 hrs at RT. Secondary antibodies (goat anti-mouse or anti-rabbit IgG-HRP conjugate (Bio-Rad) were diluted 1:10,000 and applied for 1 hour at RT. Blots were rinsed at least three times in wash buffer. Immunoreactive bands were visualized on Blue Biofilm (Denville Scientific; Metuchen, NJ) after the application of SuperSignal West Pico Stable or West Femto Stable ECL substrate (Pierce; Rockford, IL). Finally, the efficiency of protein transfer to blots was assessed by staining membranes with the MemCode protein stain (Pierce; Rockford, IL). Immunoprecipitation of CFTR followed the protocol described by Ward et al. (1995). cDNA constructs and transfections Constructs expressing various hook2 and hook3 wild-type or mutant proteins have been described [20,21]. In brief, the constructs 223, 322, 332, 233, 323, and 232 are chimeras of hook2 and hook3: 223 contains hook2 aa 1–567 and hook3 aa 573–719; 322 contains hook3 aa 1–213 and hook2 aa 210–719; 332 contains hook3 aa 1–572 and hook3 aa 567–719; 233 contains hook2 aa 1–210 and hook3 aa 215–719; 323 is hook3 with a hook2 insert from aa 213 to 572; 232 is hook2 with a hook3 insert from aa 210 to 567. Chimeras were designed to approximate locations of the previously mapped N-terminal microtubule binding region, the central coiled-coil homodimerization domain, and the proposed organelle binding C-terminal domain boundaries [20-22]. ΔC-hook2, ΔN-hook2 and ΔCl-hook2 are deletion constructs of hook2: from ΔC-hook2 aa 533–719 were deleted, from ΔN-hook2 aa 1–161, and from ΔCl-hook2 aa 439–554, including 507–548 that comprises the C-terminal region of the coil-coil domain. Each of the constructs was inserted into mammalian expression vector pcDNA3.1 that contains a CMV promoter (Invitrogen, Carlsbad, CA; invitrogen.com). Plasmids pCMVNot6.2 and pCMVNot6.2-ΔF508 containing expressible human CFTR cDNAs were the generous gift of Dr. Johanna Rommens (The Hospital For Sick Children, Toronto). A construct expressing a GFP-tagged CFTR [38] was a gift of Bruce Stanton (Dartmouth Medical School). Vero and HEK cells were transfected with Fugene (Roche; Indianapolis, IN) using a ratio of 1 μg DNA per 3 μl Fugene for HEK cells and a 1:6 ratio for Vero cells. Differential detergent extraction of live cells and preparation of whole cell lysates Vero cells grown on 35–60 mm plates were placed on a slide warmer and rinsed several times with 37°C PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, and 1 mM MgCl2, pH 7.4). Cells were sequentially extracted for 3 min with increasing concentrations of detergents (0.1% and 1% Triton X-100 and finally 1% SDS) in 100–300 μl PHEM buffer containing protease inhibitors for mammalian cells (Roche; Indianapolis, IN). Each fraction was centrifuged at 20,000 × g and supernatants of each fraction and in some cases the pellet of the 1% SDS fraction were further solubilized in loading buffer with 6% SDS prior to loading. Whole-cell lysates were obtained by scraping cells directly into loading buffer after washes in serum-free medium at 37°C. Immunocytochemistry and microscopy For immunohistochemistry, cells grown on 4-well Lab-Tek II chamber slides (Nalgene-Nunc) up to a density of ~5000 cells/cm2 were rinsed with PHEM buffer at 37°C, then fixed in methanol at -20°C for 8 min. After two rinses with PBS, formaldehyde-fixed cells were permeabilized in 0.2% Triton X-100 in PBS for 10 min at room temperature. Nonspecific binding was blocked with 2.5% gelatin/3% BSA/0.2 Triton X-100 in PBS pH 7.4 for at least 45 min at 37°C. Antibodies were diluted in blocking solution; primary antibodies were applied overnight at 4°C and secondary antibodies for 1 hr at room temperature. Washes were in 0.2% Tween-20 in PBS. Nuclei were stained with 0.5 μg/ml Hoechst (Aldrich Chemicals, St. Louis, MO). After rinses in 50 mM Tris (pH 8.0), sections were mounted with Gel/Mount (Biomedia, Foster City, CA). Fluorescent cell preparations were viewed through 20× (NA 0.5), 40× (NA 1.0) or 100× (NA. 1.3) PL/Fluotar Leica objectives on a Leica Leitz, DMR microscope (Thornwood, NY). Images were captured with an AxioCam camera (Zeiss) controlled by Axiovision 3.0. All images used for determining the co-localization of proteins were captured in sequential mode with a Leica CS SP2 confocal scanner on a Leica DMIRE2 microscope through a 63× HCX PL APO (NA1.32) objective. Images were assembled into panels in Adobe Photoshop (Adobe Systems, Mountain View, CA) and all images within a panel were adjusted together for contrast and brightness. Authors' contributions GS performed the majority of the biochemical and cell analytical experiments with the help of MY and BH. GS organized and analyzed data, and drafted the initial manuscript. AD performed the initial experiments revealing an effect of hook2 on CFTR. HK designed and constructed plasmids and MY prepared DNA. WCW performed experiment shown in figure 6B. GS, HK and PT designed experiments. GS and HK finalized the manuscript and discussed it with the other authors. Acknowledgements We thank Dr. Bruce Stanton for the CFTR-GFP expression construct, and Drs. Andreas Merdes, Gordon Chan and Michel Bornens for providing antibodies. This work was supported by grants to H.K. from The Welch Foundation (I-1300), and the NIH (NS43406) and to P.T. (DK49835). References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||
Nature. 2003 Dec 18; 426(6968):895-9.
[Nature. 2003]Neuron. 2003 Sep 25; 40(1):25-40.
[Neuron. 2003]Science. 2001 May 25; 292(5521):1552-5.
[Science. 2001]J Cell Biol. 1999 Sep 20; 146(6):1239-54.
[J Cell Biol. 1999]Traffic. 2002 Jun; 3(6):388-96.
[Traffic. 2002]J Cell Biol. 1999 May 3; 145(3):481-90.
[J Cell Biol. 1999]Traffic. 2002 Jun; 3(6):388-96.
[Traffic. 2002]Mol Biol Cell. 2001 May; 12(5):1393-407.
[Mol Biol Cell. 2001]J Cell Biol. 1998 Dec 28; 143(7):1883-98.
[J Cell Biol. 1998]J Cell Biol. 1999 May 3; 145(3):481-90.
[J Cell Biol. 1999]Neuron. 2001 Jan; 29(1):15-32.
[Neuron. 2001]EMBO J. 2004 Oct 27; 23(21):4156-65.
[EMBO J. 2004]J Biol Chem. 1994 Oct 14; 269(41):25710-8.
[J Biol Chem. 1994]Cell. 1995 Oct 6; 83(1):121-7.
[Cell. 1995]Cell. 1995 Oct 6; 83(1):129-35.
[Cell. 1995]J Cell Biol. 1998 Dec 28; 143(7):1883-98.
[J Cell Biol. 1998]Curr Opin Cell Biol. 2003 Feb; 15(1):60-6.
[Curr Opin Cell Biol. 2003]Curr Biol. 2004 Apr 6; 14(7):R268-70.
[Curr Biol. 2004]J Cell Biol. 2001 Mar 5; 152(5):923-34.
[J Cell Biol. 2001]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]J Cell Biol. 1996 Jun; 133(6):1205-15.
[J Cell Biol. 1996]Genetics. 1999 Feb; 151(2):675-84.
[Genetics. 1999]Cell. 2003 Dec 26; 115(7):825-36.
[Cell. 2003]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]J Cell Biol. 1998 Dec 28; 143(7):1883-98.
[J Cell Biol. 1998]J Cell Biol. 1999 May 3; 145(3):481-90.
[J Cell Biol. 1999]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]J Biol Chem. 1998 Apr 10; 273(15):8545-8.
[J Biol Chem. 1998]J Cell Biol. 1999 Sep 20; 146(6):1239-54.
[J Cell Biol. 1999]Cell Motil Cytoskeleton. 2002 Sep; 53(1):26-38.
[Cell Motil Cytoskeleton. 2002]J Cell Biol. 1999 Sep 20; 146(6):1239-54.
[J Cell Biol. 1999]J Cell Biol. 1996 Jun; 133(6):1205-15.
[J Cell Biol. 1996]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]J Cell Biol. 1998 Dec 28; 143(7):1883-98.
[J Cell Biol. 1998]J Cell Biol. 1999 May 3; 145(3):481-90.
[J Cell Biol. 1999]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]Cell. 1995 Oct 6; 83(1):121-7.
[Cell. 1995]Cell. 1995 Oct 6; 83(1):129-35.
[Cell. 1995]Nat Struct Biol. 2002 May; 9(5):381-8.
[Nat Struct Biol. 2002]Cell. 2004 Aug 6; 118(3):271-2.
[Cell. 2004]J Cell Biol. 1999 Sep 20; 146(6):1239-54.
[J Cell Biol. 1999]Cell Motil Cytoskeleton. 2002 Sep; 53(1):26-38.
[Cell Motil Cytoskeleton. 2002]Genetics. 1999 Feb; 151(2):675-84.
[Genetics. 1999]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]Traffic. 2002 Jun; 3(6):388-96.
[Traffic. 2002]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]Proc Natl Acad Sci U S A. 2001 Nov 6; 98(23):13060-5.
[Proc Natl Acad Sci U S A. 2001]Science. 2001 May 25; 292(5521):1552-5.
[Science. 2001]Mol Cell. 2005 Feb 4; 17(3):351-65.
[Mol Cell. 2005]Cell. 1995 Oct 6; 83(1):121-7.
[Cell. 1995]Cell. 1995 Oct 6; 83(1):129-35.
[Cell. 1995]J Cell Biol. 1999 Sep 20; 146(6):1239-54.
[J Cell Biol. 1999]Cell Motil Cytoskeleton. 2002 Sep; 53(1):26-38.
[Cell Motil Cytoskeleton. 2002]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]Cell. 2003 Dec 26; 115(7):825-36.
[Cell. 2003]Curr Opin Cell Biol. 2003 Feb; 15(1):60-6.
[Curr Opin Cell Biol. 2003]Cell. 2004 Aug 6; 118(3):271-2.
[Cell. 2004]Cell. 2004 Aug 6; 118(3):323-35.
[Cell. 2004]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]J Cell Biol. 2001 Mar 5; 152(5):923-34.
[J Cell Biol. 2001]J Cell Biol. 1997 Oct 20; 139(2):469-84.
[J Cell Biol. 1997]Nature. 1997 Sep 4; 389(6646):81-5.
[Nature. 1997]Hum Mol Genet. 2002 Jul 1; 11(14):1647-58.
[Hum Mol Genet. 2002]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]Traffic. 2000 Dec; 1(12):927-34.
[Traffic. 2000]Curr Opin Cell Biol. 2002 Feb; 14(1):25-34.
[Curr Opin Cell Biol. 2002]J Biol Chem. 2000 Oct 20; 275(42):32763-8.
[J Biol Chem. 2000]J Cell Biol. 2005 Feb 28; 168(5):697-703.
[J Cell Biol. 2005]J Cell Biol. 2001 Mar 5; 152(5):923-34.
[J Cell Biol. 2001]Cell. 2003 Dec 26; 115(7):825-36.
[Cell. 2003]Hum Mol Genet. 2002 Jul 1; 11(14):1647-58.
[Hum Mol Genet. 2002]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]J Cell Biol. 2001 Mar 5; 152(5):923-34.
[J Cell Biol. 2001]J Cell Biol. 2001 Mar 5; 152(5):923-34.
[J Cell Biol. 2001]Traffic. 2007 Jan; 8(1):32-46.
[Traffic. 2007]J Cell Biol. 1996 Jun; 133(6):1205-15.
[J Cell Biol. 1996]J Biol Chem. 1998 Aug 21; 273(34):21759-68.
[J Biol Chem. 1998]